Press Coverage

All press coverage

EP 3 996 688 Maintained as Granted: Maiwald Successfully Defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.